Skip to content
VisionGate LogoVisionGate LogoVisionGate Logo
  • Home
  • About
    • Our Team
  • Our Technology
    • Non-Intrusive Testing
    • Patented Cell-CT Imaging
    • AI Powered Detection
  • Blog
    • News
    • Patents
    • Publications
    • Research
  • Contact

Blog

  • NewsFPO
  • Patents
  • Publications
  • ResearchFPO
  • September 9, 2023

    VisionGate Presents at the World Conference on Lung Cancer for 2023 in Singapore: PneuVision® Sputum Test for Lung Cancer Detects True Abnormal Cells in Non-cancer Patients with Near 100% Specificity

    More Information

    Research

  • January 16, 2023

    IRB approves a new clinical study between Northwestern University Feinberg School of Medicine and VisionGate

    More Information

    News

  • January 10, 2023

    #11,551,043:
    MORPHOMETRIC DETECTION OF MALIGNANCY ASSOCIATED CHANGE

    More Information

    Patents

  • January 3, 2023

    #11,545,237:
    MORPHOMETRIC GENOTYPING OF CELLS IN LIQUID BIOPSY USING OPTICAL TOMOGRAPHY

    More Information

    Patents

  • August 30, 2022

    #11,428,692:
    SPECIMEN ENRICHMENT FOR OPTICAL TOMOGRAPHY CELL ANALYSIS

    More Information

    Patents

  • August 6, 2022

    VisionGate Presents at the World Conference on Lung Cancer for 2022 in Vienna: New Assay for Smoking Status Based on 3D Imaging of Pulmonary Macrophages

    More Information

    Research

  • September 22, 2021

    VisionGate’s New Website Illustrates its Mission to Save Lives through Early Detection of Lung Cancer

    More Information

    News

  • September 8, 2021

    VisionGate Presents at the World Conference on Lung Cancer for 2021: Non-Intrusive LuCED® Test for Detection of Early-Stage Lung Cancer: Subgroup Analysis for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    More Information

    Research

  • July 20, 2021

    #11,069,054:
    SYSTEM AND METHOD FOR AUTOMATED DETECTION AND MONITORING OF DYSPLASIA AND ADMINISTRATION OF CHEMOPREVENTION

    More Information

    Patents

  • January 28, 2021

    VisionGate Presents at the World Conference on Lung Cancer for 2020: LuCED® Sputum Test for Assessment of Lung Cancer Risk in COPD Patients: Sensitivity and Specimen Satisfactory Rate

    More Information

    Research

Previous123Next
visiongate logo retina logo

Follow Us

x icon
  • Home
  • About
  • Our Technology
Contact

17280 Woodinville-Redmond Rd. NE Suite 800
Woodinville, WA 98072-9088

© Copyright 2005 – 2025 | VisionGate, Inc | Milwaukee Web Design by Flipeleven | All Rights Reserved

3 Questions to Assess Your Risk

 Early detection of lung cancer is important to keeping you healthy and living your life to the fullest.

Has a family member had Lung Cancer? *
Have you smoked or been exposed to secondhand smoke? *

If you are over the age of 60 or answer "Yes" to any of the questions above, you may be at an increased risk.

This test is not a diagnosis but can help you recognize factors that may increase your risk of developing lung cancer. Next, You can subscribe to learn more from VisionGate. Then, you'll be redirected to a page of resources that can aid you in discussions with your doctor, or click here to access the page directly.

If you are above the age of 50 and answered "Yes" to any of the questions, you may be at an increased risk of developing lung cancer, but this is not a diagnosis. Use the link below to download resources that can help you talk to your doctor. Click Here to Download
We're sorry! There was an error submitting the test. Please try again later.

*No personal information is collected or saved through this form without your consent. Only your email and name will be saved if you opt-in.

visiongate logo
Contact
  • Home
  • About
  • Our Technology

© Copyright 2005 – 2025 | VisionGate, Inc | Milwaukee Web Design by Flipeleven | All Rights Reserved

Page load link
Go to Top